ClinicalTrials.gg
RecruitingNCT06386354PorceritoUpdated Aug 24, 2025

Residual Neuromuscular Block in the Post-Anesthetic Unit and Postoperative Complications

An observational study in Postoperative Neuromuscular Block and Postoperative Complications, sponsored by Hospital Universitario de Gran Canaria Doctor Negrín. Recruiting at 2 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-24.

Sponsored by Hospital Universitario de Gran Canaria Doctor Negrín · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
296
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Postoperative Complications with a site in Spain — 13 open to participants now, 15 under way, 1 of them phase 3. Postoperative Complications · Spain.

Planned enrollment
23rd of 37
296 · median 400
Started
2024
with 2 others
Observational
37 of 69
4 open now
Primary completion
2025-10
later than 2 of 14 live
Registered
59th of 69
by date
Lead sponsor
2 of 69
Hospital Universitario de Gran Canaria Doctor Negrín

Among the 69 studies in Postoperative Complications with a site in Spain, this one is the 23rd largest by planned enrollment of the 37 observational ones that give a count, is one of 3 that started in 2024, is one of 37 observational ones, reaches primary completion later than 2 of the 14 other live ones, and was the 59th registered.

Postoperative Complications

1,343 studies on the registry are indexed under Postoperative Complications; 314 are open to participants now.

Browse Postoperative Complications studies →

Open to participants now

13 of the 69 studies in Postoperative Complications with a site in Spain are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 200 Postoperative Complications studies recruiting now, 126 (63%) set no upper age limit and 31 (16%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Postoperative Complications with a site in Spain, or all of them as a file.
02

Study summary

The use of neuromuscular blockers (NMB) is essential to optimize surgical conditions, ensure patient immobility during the intervention and prevent complications derived from involuntary movements. Intraoperative monitoring of neuromuscular relaxation allows the depth of neuromuscular blockade to be accurately evaluated, guaranteeing ideal conditions for the surgical team. Residual neuromuscular blockade (RNMB) is the persistence of muscle paralysis after the administration of NMB during a surgical intervention. The appearance of RNMB poses substantial challenges in the postoperative period, as it has negative repercussions for the safety and well-being of the patient.

Read the detailed description

The use of neuromuscular blockers (NMB) is essential to optimize surgical conditions, ensure patient immobility during the intervention and prevent complications derived from involuntary movements. Intraoperative monitoring of neuromuscular relaxation allows the depth of neuromuscular blockade to be accurately evaluated, guaranteeing ideal conditions for the surgical team. Residual neuromuscular blockade (RNMB) is the persistence of muscle paralysis after the administration of NMB during a surgical intervention. The appearance of RNMB poses substantial challenges in the postoperative period, as it has negative repercussions for the safety and well-being of the patient. In this prospective observational study, all patients who underwent general anesthesia with neuromuscular blockade were studied consecutively to evaluate the presence of residual neuromuscular blockade and its potential consequences during hospital admission.Considering that the percentage of residual curarization is 19% (PORCzero study), with a 95% confidence interval and a 3% error margin, 236 patients are needed to accurately estimate the prevalence of residual curarization in the study population. With an expected loss proportion of 20%, the chosen sample size is 296 patients.

03

Conditions studied

  • Postoperative Neuromuscular Block
  • Postoperative Complications

Keywords

  • General Anesthesia
  • Neuromuscular block
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients undergoing surgical intervention under general anesthesia that requires the use of neuromuscular block during the study time.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient undergoing surgical intervention under general anesthesia that requires the use of neuromuscular block during the study time and that required hospital admission.
  • signature.

Exclusion criteria

Exclusion Criteria:

  • Neuromuscular disease
  • Not having received neuromuscular block during the intervention
  • Admission to the outpatient surgery unit
  • Admission to the postoperative intensive care unit
  • Patients who signed , but postoperative data could not be collected upon arrival at the PACU.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
296 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients submitted to General Anesthesia with Neuromuscular Block

    Patients submitted to General Anesthesia with Neuromuscular Block

    Diagnostic Test: Train-of-four

Interventions

  • Diagnostic testTrain-of-four

    Patients submitted to general anesthesia with neuromuscular block will be monitored at their arrival to the Post-Anesthesia Care Unit to assess the presence of residual neuromuscular block.

06

What researchers measure

Primary outcomes

  1. Residual Neuromuscular Block

    Train-Of-Four ratio at arrival to the Post-Anesthetic Care Unit

    Time frame: 5 minutes postoperatively

  2. Residual Neuromuscular Block

    Train-Of-Four ratio 3 minutes after the arrival to the Post-Anesthetic Care Unit

    Time frame: 8 minutes postoperatively

Secondary outcomes

  1. Postoperative complications

    Postoperative complications during hospital admission

    Time frame: 30 days postoperatively

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Oct 2025, 17 months after the start.

Of 276 non-industry observational studies under Postoperative Complications, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's planned 17 months is below that.

Counting every sponsor, half of 281 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2024
First posted
Apr 26, 2024
StartActual
May 1, 2024
Primary completionEst.
Oct 30, 2025
CompletionEst.
Oct 30, 2025
Last update
Aug 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06386354
Lead sponsor
Hospital Universitario de Gran Canaria Doctor Negrín
Responsible party
Ángel Becerra-Bolaños, MD PhD (PhD, Hospital Universitario de Gran Canaria Doctor Negrín) — Principal investigator
First posted
Apr 26, 2024
Start date
May 1, 2024
Primary completion
Oct 30, 2025 (estimated)
Completion
Oct 30, 2025 (estimated)
Last update
Aug 24, 2025

Study contacts

Ángel Becerra Bolaños, PhD
Contact
angbecbol@gmail.com
+34928450370
Aurelio Rodríguez Pérez, PhD
Contact
arodperp@gobiernodecanarias.org
+34928450370

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion